Halozyme Therapeutics | HALO - DEBITO





DEBITO Cambiamento Data
Acadia Pharmaceuticals USD 52.19M 2.62M 2025-12
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Amarin USD 0 0 2025-03
Amgen USD 54.6B 17M 2025-12
Baxter International USD 9.78B 68M 2025-12
Cara Therapeutics USD 0 0 2025-03
Cytokinetics USD 1.29B 4.48M 2026-03
DBV Technologies USD 6.1M 2.49M 2026-03
Eli Lilly USD 42.5B 3.6M 2025-12
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Intrexon USD 0 13.82M 2024-06
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
MannKind USD 367.44M 247.53M 2025-12
Minerva Neurosciences USD 0 0 2024-09
Nektar Therapeutics USD 0 0 2022-06
Pfizer USD 63.73B 231M 2026-03
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
United Therapeutics USD 200M 100M 2025-03
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12